ResMed (NYSE: RMD) was upgraded by investment analysts at Feltl & Co. from a “hold” rating to a “buy” rating in a note issued to investors on Friday. The firm currently has a $38.00 target price on the stock.
Shares of ResMed opened at 34.12 on Friday. ResMed has a one year low of $23.37 and a one year high of $35.32. The company has a market cap of $4.920 billion and a P/E ratio of 23.38.
The company last announced its quarterly results on Thursday, April 26th. It reported $0.44 earnings per share (EPS) for the previous quarter, beating the Thomson Reuters consensus estimate of $0.41 EPS by $0.03. The company’s quarterly revenue was up 11.5% on a year-over-year basis. On average, analysts predict that ResMed will post $0.42 earnings per share next quarter.
Separately, analysts at Mizuho raised their price target on shares of ResMed from $28.00 to $32.00 in a research note to investors on Friday. They now have a “neutral” rating on the stock.
ResMed Inc. (ResMed), is a holding company for the ResMed Group. The Company, through its subsidiaries, is a developer, manufacturer and distributor of medical equipment for treating, diagnosing, and managing sleep-disordered breathing and other respiratory disorders.